This segment focuses on the research and development of novel therapies for various types of cancer. ABVC BioPharma is actively involved in developing ABV-1501, a combination therapy for triple-negative breast cancer, and is strengthening its oncology partnerships. Research and development activities include preclinical studies, clinical trials, and the evaluation of biomarkers. The company utilizes advanced technologies and methodologies in drug discovery and development, including targeted therapies and combination approaches. The patient impact is significant, as these therapies aim to improve survival rates and quality of life for cancer patients. ABVC BioPharma's market positioning involves strategic collaborations and licensing agreements to expand its oncology portfolio and global footprint. Future opportunities include expanding the pipeline with additional oncology assets and securing regulatory approvals. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations with research institutions and other companies are crucial for advancing the oncology pipeline.

This segment concentrates on developing treatments for neurological and psychiatric disorders, including major depressive disorders (ABV-1504) and attention deficit hyperactivity disorder (ADHD) (ABV-1505). Research and development efforts involve conducting clinical trials to assess the safety and efficacy of these drug candidates. The company utilizes advanced methodologies in drug discovery and development, including identifying and targeting specific neurological pathways. The therapeutic areas covered include major depressive disorders and ADHD, with the goal of improving patient outcomes and quality of life. ABVC BioPharma aims to position itself as a provider of innovative treatments for these conditions, addressing unmet medical needs. Future opportunities include expanding the pipeline with additional neurological and psychiatric assets and securing regulatory approvals. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials. Partnerships and collaborations with research institutions and other companies are essential for advancing the neurology and psychiatry pipeline.

This segment focuses on developing treatments for ophthalmic conditions, including Vitargus® (ABV-1701) for the treatment of retinal detachment or vitreous hemorrhage. Research and development activities include preclinical studies and clinical trials to assess the safety and efficacy of the product. The company utilizes advanced technologies and methodologies in drug development, including targeted therapies for retinal diseases. The therapeutic area covered is ophthalmology, with the goal of improving patient outcomes and preserving vision. ABVC BioPharma aims to position itself as a provider of innovative treatments for ophthalmic conditions. Future opportunities include expanding the pipeline with additional ophthalmic assets and securing regulatory approvals. Regulatory and clinical aspects involve navigating the FDA approval process and conducting clinical trials. Partnerships and collaborations with research institutions and other companies are essential for advancing the ophthalmology pipeline.